In the past decade, many Indians have embraced the equity culture and started investing in stocks and equity mutual funds. Some analysts feel that retail investors should put money in unlisted shares if they want outsized returns. Other financial advisers say retail investors should not dabble in unlisted shares for the simple reason that the risk they entail is not worth the rewards they offer.
This weeks ETtech newsbreak on PharmEasy going for a rights issue at a price 90% lower than its peak valuation of $5.6 billion to repay debt has tripped alarm bells in several startups that have taken debt financing.
Happy Friday! Arokiaswamy Velumani, founder of Thyrocare, which was acquired by PharmEasy in 2021, had secured anti-dilution rights when he invested in the epharmacy startup. We have details on that, and more in todays ETtech Morning Dispatch.
PharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per share that it secured in 2021. The huge fall in value has triggered questions about the fate of Velumanis purchase of a 5% stake in the firm in 2021 when it was valued at $4 billion.